Researchers at Boston University and Boston Medical Center reported a scalable stem-cell approach to generate functional CD4+ helper T cells for next-generation CAR T designs. In a Stem Cell Reports study, the team used induced pluripotent stem cells and Notch signaling modulation to produce effector CD4+ populations at scale. The strategy centers on removing Notch activity during later maturation steps while reducing anti-T-cell receptor signaling, allowing developing cells to survive and differentiate into CD4+ lineages with broad T-cell subtype repertoires. The work aims to support off-the-shelf CAR T manufacturing by reducing patient-specific cell collection. For cell-therapy developers, the report provides a practical manufacturing lever for CD4 biology—an increasingly recognized component for coordinated immune responses—while setting the stage for direct CAR integration and in vivo efficacy testing.